Literature DB >> 31402166

Sentinel lymph node biopsy with cervical injection of indocyanine green in apparent early-stage endometrial cancer: predictors of unsuccessful mapping.

Lucia Tortorella1, Jvan Casarin2, Francesco Multinu2, Serena Cappuccio2, Michaela E McGree3, Amy L Weaver3, Carrie L Langstraat2, Gary L Keeney4, Amanika Kumar2, Gian Benedetto Melis5, Stefano Angioni5, Giovanni Scambia6, Andrea Mariani2, Gretchen E Glaser7.   

Abstract

OBJECTIVE: To identify predictors of unsuccessful sentinel lymph node (SLN) mapping in patients with apparent early-stage endometrial cancer (EC) undergoing surgical staging with cervical injection of indocyanine green and SLN biopsy.
METHODS: We retrospectively identified consecutive patients with EC with attempted SLN biopsy between June 2014 and June 2016 at our institution. Patients were grouped according to whether they had a successful procedure, defined as the bilateral identification of SLNs, or an unsuccessful procedure, defined as unilateral or no SLN mapping. Logistic regression was used to evaluate predictors of an unsuccessful procedure.
RESULTS: Among 327 patients included in the analysis, 256 (78.3%) had a successful procedure and 71 (21.7%) had an unsuccessful procedure (15.0% unilateral SLN mapping, 6.7% no mapping). The rate of successful procedure increased from 57.7% to 83.3% between the first and last quarters of the 2-year study period, which represented the learning curve for the technique. The mean (SD) operative time decreased from 164 (55) to 137 (37) minutes. By multivariable analysis, lysis of adhesions at the beginning of surgery (odds ratio, 3.07; 95% CI, 1.56-6.07) and the presence of enlarged lymph nodes (odds ratio, 4.69; 95% CI, 1.82-12.11) were independently associated with an unsuccessful procedure.
CONCLUSIONS: Lysis of adhesions at the beginning of surgery and the presence of enlarged lymph nodes independently affect the bilateral detection of SLNs.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endometrial cancer; Indocyanine green; Lymph nodes; Sentinel lymph node mapping; Stage I

Mesh:

Substances:

Year:  2019        PMID: 31402166     DOI: 10.1016/j.ygyno.2019.08.008

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Sentinel lymph node detection in endometrial cancer with indocyanine green: laparoscopic versus robotic approach.

Authors:  N Bizzarri; S Restaino; S Gueli Alletti; G Monterossi; A Gioè; E La Fera; V Gallotta; A Fagotti; G Scambia; F Fanfani
Journal:  Facts Views Vis Obgyn       Date:  2021-03-31

2.  Sentinel Lymph Node in Aged Endometrial Cancer Patients "The SAGE Study": A Multicenter Experience.

Authors:  Stefano Cianci; Andrea Rosati; Virginia Vargiu; Vito Andrea Capozzi; Giulio Sozzi; Alessandro Gioè; Salvatore Gueli Alletti; Alfredo Ercoli; Francesco Cosentino; Roberto Berretta; Vito Chiantera; Giovanni Scambia; Francesco Fanfani
Journal:  Front Oncol       Date:  2021-10-19       Impact factor: 6.244

3.  Pathological processing of sentinel lymph nodes in endometrial carcinoma - routine aspects of grossing, ultra-staging, and surgico-pathological parameters in a series of 833 lymph nodes.

Authors:  Tilman T Rau; Mona V Deppeler; Lucine Christe; Franziska Siegenthaler; Sara Imboden; Andrea Papadia; Michael D Mueller
Journal:  Virchows Arch       Date:  2022-07-19       Impact factor: 4.535

4.  Clinical factors associated with failed sentinel lymph node mapping in endometrial cancer.

Authors:  Alison A Garrett; Alyssa Wield; Brigid Mumford; Isabel Janmey; Li Wang; Philip Grosse; Emily MacArthur; Ronald Buckanovich; Madeleine Courtney-Brooks; Paniti Sukumvanich; Jessica Berger; Alexander B Olawaiye; Haider Mahdi; Michelle Boisen; Robert P Edwards; Lan Coffman; Sarah E Taylor; Jamie Lesnock
Journal:  Gynecol Oncol Rep       Date:  2022-10-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.